Roy, Vivek

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell

Multiple Myeloma Research and TreatmentsCancer Genomics and Diagnostics

Cited by 988

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 628

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Gastineau, D. A., Litzow, M. R., Fonseca, R., Roy, V, Rajkumar, S. V., et al. (2007) · Leukemia

Multiple Myeloma Research and TreatmentsHematopoietic Stem Cell Transplantation

Cited by 351

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 317

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 222

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 197

Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

Hari, P. N., Zhang, M.-J., Roy, V, Pérez, W. S., Bashey, A., To, L. B., Elfenbein, G., Freytes, C. O., Gale, R. P., Gibson, J., et al. (2009) · Leukemia

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 100

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 95